ecancermedicalscience

Conference Report

Aspirin for the next generation

2 Apr 2013
Nick Henderson, Tom Smith

First used as an analgesic and antipyretic, investigations into aspirin’s anti-inflammatory effects led to its establishment in 1974 as a drug that altered the activity of platelets to influence the course and incidence of myocardial infarction and cerebrovascular disease. It became the standard in treatment and prevention of vascular disorders.

The 25th International Scientific Meeting on aspirin held at the Royal College of Physicians in London on 24th October 2012 took aspirin into fresh fields, among them cancer, diabetes, dementia and gynaecology.

Related Articles

Pallavi Rajput, Vandita Pahwa, Charu Singh, Sankalp Sancheti, Ravikiran Pawar, Shikha Jain, Gurwinder Kaur, Kundan Rao, Navin Bansal, Rahat Brar, Tapas Dora, Ashish Gulia
Zakayo Ernesti, Emanuel Lugina, Chacha J Mwita, Felister Tupa, Herriethsiah S Noah, John R Ngowi, Charles Wood, Julius Mwaiselage, Salum J Lidenge
Sandro Casavilca-Zambrano, Juan Contreras-Mancilla, Camille Laurent, Jaqueline Montoya, Rosdali Diaz-Coronado, Jorge Honles, Ruddy Liendo-Picoaga, Jenny Bonifacio-Mundaca, Jhoysi Casas-Goñas, Juan Pablo Cerapio, Carlos Barrionuevo, Tatiana Vidaurre, Stéphane Bertani
Elizabeth Hatzaw, Jane Ralte, Vignesh Krishnasamy, Lalengkimi Ralte, Rajendra Bose Muthukumaran, Kasi Marimuthu, Nachimuthu Senthil Kumar
Ravikant Singh, Atul Budukh Suvarna Kolekar, Gaurav Kumar, Burhanuddin Qayyumi, Tulika Gupta, Zikki Hassan Fatima, Narpat Padvi, Samyukta Shivashankar, Alisha Shah, Deepak Gupta, Nishant Kumar, Kumar Prabhash
M T Maria Tereza Nieto-Coronel, Daniela Shveid Gerson, Gian Karla Urey Cuellar, Navia-Bueno Ma Pilar, Maribel Marmol Casas